COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

BACKGROUND: Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshukairi, Abeer N., Al-Omari, Awad, Albeity, Abdurahman, Alandijany, Thamir A., Hassan, Ahmed M., El-Kafrawy, Sherif A., Dada, Ashraf, Al Hroub, Mohammad K., El-Saed, Aiman, Bissar, Lina S., Daghmush, Radwan M., Al-Ghamdi, Saeed M.G., Perlman, Stanley, Azhar, Esam I., Halabi, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098803/
https://www.ncbi.nlm.nih.gov/pubmed/35623243
http://dx.doi.org/10.1016/j.jiph.2022.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098803/
https://www.ncbi.nlm.nih.gov/pubmed/35623243
http://dx.doi.org/10.1016/j.jiph.2022.05.005

Ejemplares similares